ESOT Congress 2025: Scientists create functional human islets in 3D printing breakthrough for type 1 diabetes treatment

Contributed by: PR Newswire

Tags

ESOT-Diabetes

More Like This

PR Newswire associated0

FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment

The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the platform features three complexity levels: standard (cancer cells), intermediate (+fibroblasts), and advanced (+immune/endothelial cells) . A key breakthrough is its record cellular viability of 128 days, enabling unprecedented long-term studies on drug resistance and metastasis . Ultimately, CTIONCOTEST delivers a highly predictive, 100% human-derived ethical alternative to animal testing.

Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care

PR Newswire associated0

Continuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE® Cell-Therapy Platform Toward First-in-Human Study

UEG Week: Novel procedure combined with semaglutide may eliminate insulin dependency in type 2 diabetes

PR Newswire associated0

Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy

PolTREG moves forward with the European registration process for TREG therapy in type 1 diabetes

PR Newswire associated0

A Global Milestone in Innovative Pancreatic Cancer Therapy

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London